c-Myc, genome instability, and tumorigenesis: The devil is in the details

Current Topics in Microbiology and Immunology

Volumn 302, Issue , 2006, Pages 169-203

  Wade, M ^a   Wahl, G M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; DNA DAMAGE; GENE ACTIVITY; GENE EXPRESSION; GENOMIC INSTABILITY; KARYOTYPING; ONCOGENE C MYC; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL CYCLE; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION REGULATION; GENES, MYC; GENOMIC INSTABILITY; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; ONCOGENES; ONCOGENIC VIRUSES; REACTIVE OXYGEN SPECIES;

EID: 33144466315     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/3-540-32952-8_7     Document Type: Review

References (215)

1. Bishop JM (1991) Molecular themes in oncogenesis. Cell 64:235-248
2. Bodmer WF, Tomlinson I (1996) Population genetics of tumours. Ciba Found Symp 197:181-189; discussion 189-193
3. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
4. Potter M, Melchers F (eds) (1997) Proceedings of the 14th Mechanisms in B-cell Neoplasia meeting. Bethesda, Maryland, 21-23 October 21-23 1996. Current Topics in Microbiology and Immunology, vol 224. Springer-Verlag, Heidelberg Berlin New York, pp 1-291
5. Watson PH, Singh R, Hole AK (1996) Influence of c-myc on the progression of human breast cancer. In: Gunthert U, Birchmeier B (eds) Current Topics in Microbiology and Immunology, vol 213. Springer-Verlag, Heidelberg Berlin New York, pp 267-283
6. Mushinski JF, Hanley-Hyde J, Rainey GJ, Kuschak TI, Taylor C, Fluri M, Stevens LM, Henderson DW, Mai S (1999) Myc-induced cyclin D2 genomic instability in murine B cell neoplasms. In: Melchers F, Potter M (eds) Current Topics in Microbiology and Immunology, vol 246. Springer-Verlag, Heidelberg Berlin New York, pp 183-189; discussion 190-192
7. Eisenman RN (2001) Deconstructing myc. Genes Dev 15:2023-2030
8. Oster SK, Ho CS, Soucie EL, Penn LZ (2002) The myc oncogene: MarvelouslY complex. Adv Cancer Res 84:81-154
9. Lutz W, Leon J, Eilers M (2002) Contributions of Myc to tumorigenesis. Biochim Biophys Acta 1602:61-71
10. Pelengaris S, Khan M, Evan G (2002) c-myc: more than just a matter of life and death. Nat Rev Cancer 2:764-776
11. Armitage P, Doll R (1954) The age distribution of cancer and multistage theory of carcinogenesis. Br J Cancer 8:1-12
12. Tomlinson I, Bodmer W (1999) Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nat Med 5:11-12
13. Loeb KR, Loeb LA (2000) Significance of multiple mutations in cancer. Carcinogenesis 21:379-385
14. Savelyeva L, Schwab M (2001) Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer Lett 167:115-123
15. Popescu NC, Zimonjic DB (2002) Chromosome-mediated alterations of the MYC gene in human cancer. J Cell Mol Med 6:151-159
16. Wright JA, Smith HS, Watt FM, Hancock MC, Hudson DL, Stark GR (1990) DNA amplification is rare in normal human cells. Proc Natl Acad Sci U S A 87:1791-1795
17. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935
18. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948
19. Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386:623-627
20. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558-561
21. Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260:816-819
22. Jallepalli PV, Lengauer C (2001) Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer 1:109-117
23. Klein G (1999) Immunoglobulin gene associated chromosomal translocations in B-cell derived tumors. In: Melchers F, Potter M (eds) Current Topics in Microbiology and Immunology, vol 246. Springer-Verlag, Heidelberg Berlin New York, pp 161-167
24. Stark GR (1993) Regulation and mechanisms of mammalian gene amplification. Adv Cancer Res 61:87-113
25. Parsons R, Li GM, Longley M, Modrich P, Liu B, Berk T, Hamilton SR, Kinzler KW, Vogelstein B (1995) Mismatch repair deficiency in phenotypically normal human cells. Science 268:738-740
26. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1038
27. Wright WE, Shay JW (2001) Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr Opin Genet Dev 11:98-103
28. Hickman JA (2002) Apoptosis and tumourigenesis. Curr Opin Genet Dev 12:67-72
29. Balmain A, Harris CC (2000) Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis 21:371-377
30. Ross JA, Nesnow S (1999) Polycyclic aromatic hydrocarbons: correlations between DNA adducts and ras oncogene mutations. Mutat Res 424:155-166
31. Bos JL (1988) The ras gene family and human carcinogenesis. Mutat Res 195:255-271
32. Balmain A, Brown K (1988) Oncogene activation in chemical carcinogenesis. Adv Cancer Res 51:147-182
33. Nichols WW (1963) Relationships of viruses, chromosomes and carcinogenesis. Hereditas 50:53-80
34. Nowell PC (1965) Chromosome changes in primary tumors. Prog Exp Tumor Res 7:83-103
35. Loeb LA, Springgate CF, Battula N (1974) Errors in DNA replication as a basis of malignant changes. Cancer Res 34:2311-2321
36. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, et al (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368:258-261
37. Duval A, Hamelin R (2002) Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 62:2447-2454
38. Hussein MR, Sun M, Roggero E, Sudilovsky EC, Tuthill RJ, Wood GS, Sudilovsky O (2002) Loss of heterozygosity, microsatellite instability, and mismatch repair protein alterations in the radial growth phase of cutaneous malignant melanomas. Mol Carcinog 34:35-44
39. Simpson AJ, Caballero OL, Pena SD (2001) Microsatellite instability as a tool for the classification of gastric cancer. Trends Mol Med 7:76-80
40. Nichols WW, Levan A, Heneen WK, Peluse M (1965) Synergism of the Schmidt-Ruppin strain of the Rous sarcoma virus and cytidine triphosphate in the induction of chromosome breaks in human cultured leukocytes. Hereditas 54:213-236
41. Stehelin D, Guntaka RV, Varmus HE, Bishop JM (1976) Purification of DNA complementary to nucleotide sequences required for neoplastic transformation of fibroblasts by avian sarcoma viruses. J Mol Biol 101:349-365
42. Nanus DM, Lynch SA, Rao PH, Anderson SM, Jhanwar SC, Albino AP (1991) Transformation of human kidney proximal tubule cells by a src-containing retrovirus. Oncogene 6:2105-2111
43. Neil JC, Cameron ER (2002) Retroviral insertion sites and cancer: fountain of all knowledge? Cancer Cell 2:253-255
44. Tsichlis PN (1987) Oncogenesis by Moloney murine leukemia virus. Anticancer Res 7:171-180
45. Hsu T, Moroy T, Etiemble J, Louise A, Trepo C, Tiollais P, Buendia MA (1988) Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma. Cell 55:627-635
46. Kim R, Trubetskoy A, Suzuki T, Jenkins NA, Copeland NG, Lenz J (2003) Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas. J Virol 77:2056-2062
47. zur Hausen H (1991) Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184:9-13
48. Bibbo M, Montag AG, Lerma-Puertas E, Dytch HE, Leelakusolvong S, Bartels PH (1989) Karyometric marker features in tissue adjacent to invasive cervical carcinomas. Anal Quant Cytol Histol 11:281-285
49. Munger K, Howley PM (2002) Human papillomavirus immortalization and transformation functions. Virus Res 89:213-228
50. White AE, Livanos EM, Tlsty TD (1994) Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 8:666-677
51. Duensing S, Munger K (2002) The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 62:7075-7082
52. Windle B, Draper BW, Yin YX, O'Gorman S, Wahl GM (1991) A central role for chromosome breakage in gene amplification deletion formation, and amplicon integration. Genes Dev 5:160-174
53. Denko NC, Giaccia AJ, Stringer JR, Stambrook PJ (1994) The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci U S A 91:5124-5128
54. Fukasawa K, Vande Woude GF (1997) Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol 17:506-518
55. Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR, Fearon ER (2000) γ-Catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of β-catenin. Genes Dev 14:1319-1331
56. van Es JH, Barker N, Clevers H (2003) You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev 13:28-33
57. Boxer LM, Dang CV (2001) Translocations involving c-myc and c-myc function. Oncogene 20:5595-5610
58. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG (2000) c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95:2104-2110
59. Gregory MA, Hann SR (2000) c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 20:2423-2435
60. Bonilla M, Ramirez M, Lopez-Cueto J, Gariglio P (1988) In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. J Natl Cancer Inst 80:665-671
61. Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J, Callahan R (1986) Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci U S A 83:4834-4838
62. Sikora K, Chan S, Evan G, Gabra H, Markham N, Stewart J, Watson J (1987) c-myc oncogene expression in colorectal cancer. Cancer 59:1289-1295
63. Smith DR, Myint T, Goh HS (1993) Over-expression of the c-myc proto-oncogene in colorectal carcinoma. Br J Cancer 68:407-413
64. Stewart J, Evan G, Watson J, Sikora K (1986) Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer 53:1-6
65. Nagy P, Evarts RP, Marsden E, Roach J, Thorgeirsson SS (1988) Cellular distribution of c-myc transcripts during chemical hepatocarcinogenesis in rats. Cancer Res 48:5522-5527
66. Sargent LM, Sanderson ND, Thorgeirsson SS (1996) Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor alpha transgenes. Cancer Res 56:2137-2142
67. McCormack SJ, Weaver Z, Deming S, Natarajan G, Torri J, Johnson MD, Liyanage M, Ried T, Dickson RB (1998) Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene 16:2755-2766
68. Fearon ER, Gruber SB (2001) Molecular abnormalities in colon and rectal cancer. In: Mendelson J, Howley PM, Israel MA, Liotta LA (eds) The molecular basis of cancer. W.B. Saunders, Philadelphia, pp 289-312
69. Denis N, Kitzis A, Kruh J, Dautry F, Corcos D (1991) Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc. Oncogene 6:1453-1457
70. Mai S (1994) Overexpression of c-myc precedes amplification of the gene encoding dihydrofolate reductase. Gene 148:253-260
71. Mai S, Hanley-Hyde J, Fluri M (1996) c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene 12:277-288
72. Felsher DW, Bishop JM (1999) Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A 96:3940-3944
73. Mai S, Hanley-Hyde J, Rainey GJ, Kuschak TI, Paul JT, Littlewood TD, Mischak H, Stevens LM, Henderson DW, Mushinski JF (1999) Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression. Neoplasia 1:241-252
74. Kuschak TI, Taylor C, McMillan-Ward E, Israels S, Henderson DW, Mushinski JF, Wright JA, Mai S (1999) The ribonucleotide reductase R2 gene is a non-transcribed target of c-Myc-induced genomic instability. Gene 238:351-365
75. Paulson TG, Almasan A, Brody LL, Wahl GM (1998) Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage. Mol Cell Biol 18:3089-3100
76. Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW (2003) Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 101:2797-2803
77. Hynes NE (1993) Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 4:19-26
78. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB (1992) Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52:2980-2983
79. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83
80. Sargent LM, Zhou X, Keck CL, Sanderson ND, Zimonjic DB, Popescu NC, Thorgeirsson SS (1999) Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver. Am J Pathol 154:1047-1055
81. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL (1985) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533-538
82. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, Morse HC 3rd (2000) Burkitt lymphoma in the mouse. J Exp Med 192:1183-1190
83. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW (1999) INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13:2670-2677
84. Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL (2001) Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol 21:7653-7662
85. Strasser A, Harris AW, Bath ML, Cory S (1990) Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331-333
86. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW (2002) Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1:289-298
87. Rockwood LD, Torrey TA, Kim JS, Coleman AE, Kovalchuk AL, Xiang S, Ried T, Morse HC 3rd, Janz S (2002) Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations. Oncogene 21:7235-7240
88. Lindstrom MS, Wiman KG (2002) Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 12:381-387
89. Schimke RT (1986) Methotrexate resistance and gene amplification. Mechanisms and implications. Cancer 57:1912-1917
90. Schimke RT, Sherwood SW, Hill AB, Johnston RN (1986) Overreplication and recombination of DNA in higher eukaryotes: potential consequences and biological implications. Proc Natl Acad Sci U S A 83:2157-2161
91. Windle BE, Wahl GM (1992) Molecular dissection of mammalian gene amplification: new mechanistic insights revealed by analyses of very early events. Mutat Res 276:199-224
92. Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, Wagle N, Hwang DS, Dutta A (2003) A p53-dependent checkpoint pathway prevents rereplication. Mol Cell 11:997-1008
93. Watson JD, Oster SK, Shago M, Khosravi F, Penn LZ (2002) Identifying genes regulated in a Myc-dependent manner. J Biol Chem 277:36921-36930
94. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B (2003) Genomic targets of the human c-Myc protein. Genes Dev 17:1115-1129
95. Smith KA, Agarwal ML, Chernov MV, Chernova OB, Deguchi Y, Ishizaka Y, Patterson TE, Poupon MF, Stark GR (1995) Regulation and mechanisms of gene amplification. Philos Trans R Soc Lond B Biol Sci 347:49-56
96. Galloway SM (1994) Chromosome aberrations induced in vitro: mechanisms, delayed expression, and intriguing questions. Environ Mol Mutagen 23 Suppl 24:44-53
97. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM (2002) c-Myc can induce DNA damage increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9:1031-1044
98. Felsher DW, Zetterberg A, Zhu J, Tlsty T, Bishop JM (2000) Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci U S A 97:10544-10548
99. Snow EC (1997) The role of c-myc during normal B cell proliferation, and as B cells undergo malignant transformation. In: Potter M, Melchers F (eds) Current Topics in Microbiology and Immunology, vol 224. Springer-Verlag, Heidelberg Berlin New York, pp 211-220
100. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R (2001) Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A 98:7319-7324
101. Courtneidge SA (2002) Role of Src in signal transduction pathways. The Jubilee Lecture. Biochem Soc Trans 30:11-17
102. Iritani BM, Eisenman RN (1999) c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci U S A 96:13180-13185
103. Schuhmacher M, Staege MS, Pajic A, Polack A, Weidle UH, Bornkamm GW, Eick D, Kohlhuber F (1999) Control of cell growth by c-Myc in the absence of cell division. Curr Biol 9:1255-1258
104. Gomez-Roman N, Grandori C, Eisenman RN, White RJ (2003) Direct activation of RNA polymerase III transcription by c-Myc. Nature 421:290-294
105. O'Connell BC, Cheung AF, Simkevich CP, Tam W, Ren X, Mateyak MK, Sedivy JM (2003) A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 278:12563-12573
106. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV (1997) c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 94:6658-6663
107. Helbock HJ, Beckman KB, Shigenaga MK, Walter PB, Woodall AA, Yeo HC, Ames BN (1998) DNA oxidation matters: the HPLC-electrochemical detection assay of 8-oxo-deoxyguanosine and 8-oxo-guanine. Proc Natl Acad Sci U S A 95:288-293
108. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ (1997) Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275:1649-1652
109. Yang JQ, Li S, Huang Y, Zhang HJ, Domann FE, Buettner GR, Oberley LW (2001) V-Ha-Ras overexpression induces superoxide production and alters levels of primary antioxidant enzymes. Antioxid Redox Signal 3:697-709
110. Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, Machii T, Pestell RG, Kanakura Y (2002) E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell 9:1017-1029
111. Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW (2003) Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A 100(17):9974-9979
112. Xu Y, Nguyen Q, Lo DC, Czaja MJ (1997) c-myc-Dependent hepatoma cell apoptosis results from oxidative stress and not a deficiency of growth factors. J Cell Physiol 170:192-199
113. Linke SP, Clarkin KC, Wahl GM (1997) p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation. Cancer Res 57:1171-1179
114. Chen Q, Ames BN (1994) Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci U S A 91:4130-4134
115. Harley CB, Futcher AB, Greider CW (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345:458-460
116. Matsui A, Ikeda T, Enomoto K, Hosoda K, Nakashima H, Omae K, Watanabe M, Hibi T, Kitajima M (2000) Increased formation of oxidative DNA damage 8-hydroxy-2′-deoxyguanosine, in human breast cancer tissue and its relationship to GSTP1 and COMT genotypes. Cancer Lett 151:87-95
117. Gupta A, Rosenberger SF, Bowden GT (1999) Increased ROS levels contribute to elevated transcription factor and MAP kinase activities in malignantly progressed mouse keratinocyte cell lines. Carcinogenesis 20:2063-2073
118. Feig DI, Reid TM, Loeb LA (1994) Reactive oxygen species in tumorigenesis. Cancer Res 54:1890s-1894s
119. Shibutani S, Takeshita M, Grollman AP (1991) Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 349:431-434
120. Rodin SN, Rodin AS (2000) Human lung cancer and p53: the interplay between mutagenesis and selection. Proc Natl Acad Sci U S A 97:12244-12249
121. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA (1992) 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G-T and A-C substitutions. J Biol Chem 267:166-172
122. Hussain SP, Raja K, Amstad PA, Sawyer M, Trudel LJ, Wogan GN, Hofseth LJ, Shields PG, Billiar TR, Trautwein C, Hohler T, Galle PR, Phillips DH, Markin R, Marrogi AJ, Harris CC (2000) Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: oxyradical overload diseases. Proc Natl Acad Sci U S A 97:12770-12775
123. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, Harris CC (2000) Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60:3333-3337
124. Jackson AL, Chen R, Loeb LA (1998) Induction of microsatellite instability by oxidative DNA damage. Proc Natl Acad Sci U S A 95:12468-12473
125. Jackson AL, Loeb LA (2000) Microsatellite instability induced by hydrogen peroxide in Escherichia coli. Mutat Res 447:187-198
126. Huang J, Papadopoulos N, McKinley AJ, Farrington SM, Curtis LJ, Wyllie AH, Zheng S, Willson JK, Markowitz SD, Morin P, Kinzler KW, Vogelstein B, Dunlop MG (1996) APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci U S A 93:9049-9054
127. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338
128. Gasche C, Chang CL, Rhees J, Goel A, Boland CR (2001) Oxidative stress increases frameshift mutations in human colorectal cancer cells. Cancer Res 61:7444-7448
129. Zienolddiny S, Ryberg D, Haugen A (2000) Induction of microsatellite mutations by oxidative agents in human lung cancer cell lines. Carcinogenesis 21:1521-1526
130. Muir CS, Wagner G, Demaret E, Nagy-Tiborcz A, Schlaefer K, Villhauer-Lehr M, Whelan S (1982) Directory of on-going research in cancer epidemiology 1982. IARC Sci Publ, Lyon, pp 1-715
131. Murakami H, Sanderson ND, Nagy P, Marino PA, Merlino G, Thorgeirsson SS (1993) Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 53:1719-1723
132. Factor VM, Kiss A, Woitach JT, Wirth PJ, Thorgeirsson SS (1998) Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. J Biol Chem 273:15846-15853
133. Factor VM, Laskowska D, Jensen MR, Woitach JT, Popescu NC, Thorgeirsson SS (2000) Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. Proc Natl Acad Sci U S A 97:2196-2201
134. Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Martin GR, Bishop JM (2001) c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 414:768-773
135. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM (1997) Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 8:1039-1048
136. Blagosklonny MV, Pardee AB (2002) The restriction point of the cell cycle. Cell Cycle 1:103-110
137. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR (1991) The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053-1061
138. Weintraub SJ, Chow KN, Luo RX, Zhang SH, He S, Dean DC (1995) Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 375:812-815
139. Beier R, Burgin A, Kiermaier A, Fero M, Karsunky H, Saffrich R, Moroy T, Ansorge W, Roberts J, Eilers M (2000) Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events. EMBO J 19:5813-5823
140. Mateyak MK, Obaya AJ, Sedivy JM (1999) c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 19:4672-4683
141. Santoni-Rugiu E, Falck J, Mailand N, Bartek J, Lukas J (2000) Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol 20:3497-3509
142. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A (2000) Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407:592-598
143. Leone G, Sears R, Huang E, Rempel R, Nuckolls F, Park CH, Giangrande P, Wu L, Saavedra HI, Field SJ, Thompson MA, Yang H, Fujiwara Y, Greenberg ME, Orkin S, Smith C, Nevins JR (2001) Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell 8:105-113
144. Dulic V, Lees E, Reed SI (1992) Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257:1958-1961
145. Hatakeyama M, Brill JA, Fink GR, Weinberg RA (1994) Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev 8:1759-1771
146. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA (1992) Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006
147. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231-234
148. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227-230
149. Martins CP, Berns A (2002) Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J 21:3739-3748
150. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M (1999) Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 13:1181-1189
151. Vlach J, Hennecke S, Amati B (1997) Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 16:5334-5344
152. Nguyen H, Gitig DM (1999) Koff Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. Mol Cell Biol 19:1190-1201
153. Carrano AC, Eytan E, Hershko A, Pagano M (1999) SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1:193-199
154. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H (1999) p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 9:661-664
155. O'Hagan RC, Ohh M, David G, de Alboran IM, Alt FW, Kaelin WG Jr, DePinho RA (2000) Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev 14:2185-2191
156. Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B (1996) Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J 15:6595-6604
157. Alevizopoulos K, Vlach J, Hennecke S, Amati B (1997) Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J 16:5322-5333
158. Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401:297-300
159. Walter J, Sun L, Newport J (1998) Regulated chromosomal DNA replication in the absence of a nucleus. Mol Cell 1:519-529
160. Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, Doxsey SJ (1998) Centrosome defects and genetic instability in malignant tumors. Cancer Res 58:3974-3985
161. Hua XH, Yan H, Newport J (1997) A role for Cdk2 kinase in negatively regulating DNA replication during S phase of the cell cycle. J Cell Biol 137:183-192
162. Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK, Knudsen ES (2002) Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem 277:44376-44384
163. Lengronne A, Schwob E (2002) The yeast CDK inhibitor Sic1 prevents genomic instability by promoting replication origin licensing in late G(1). Mol Cell 9:1067-1078
164. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA (2002) Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 36:617-656
165. Huang LC, Clarkin KC, Wahl GM (1996) Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci U S A 93:4827-4832
166. Wahl GM, Carr AM (2001) The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 3:E277-E286
167. D'Amours D, Jackson SP (2002) The Mre11 complex: at the crossroads of DNA repair and checkpoint signalling. Nat Rev Mol Cell Biol 3:317-327
168. Mirzoeva OK, Petrini JH (2001) DNA damage-dependent nuclear dynamics of the Mre11 complex. Mol Cell Biol 21:281-288
169. Petrini JH (1999) The mammalian Mre11-Rad50-nbs1 protein complex: integration of functions in the cellular DNA-damage response. Am J Hum Genet 64:1264-1269
170. Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499-506
171. Mirzoeva OK, Petrini JH (2003) DNA replication-dependent nuclear dynamics of the mre11 complex. Mol Cancer Res 1:207-218
172. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674-1677
173. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ (2000) Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A 97:10389-10394
174. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN (1998) Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 273:33048-33053
175. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M, Haupt Y (1999) Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 18:1805-1814
176. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin- dependentkinases. Cell 75:805-816
177. Sheen JH, Dickson RB (2002) Overexpression of c-Myc alters G(1)/S arrest following ionizing radiation. Mol Cell Biol 22:1819-1833
178. Hermeking H, Eick D (1994) Mediation of c-Myc-induced apoptosis by p53. Science 265:2091-2093
179. Seoane J, Le HV, Massague J (2002) Myc suppression of the p21 (Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419:729-734
180. Li Q, Dang CV (1999) c-Myc overexpression uncouples DNA replication from mitosis. Mol Cell Biol 19:5339-5351
181. Shim J, Lee H, Park J, Kim H, Choi EJ (1996) A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 381:804-806
182. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S (1999) Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 18:1223-1234
183. Di Leonardo A, Linke SP, Clarkin K, Wahl GM (1994) DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8:2540-2551
184. Allan LA, Duhig T, Read M, Fried M (2000) The p21(WAF1/CIP1) promoter is methylated in Rat-1 cells: stable restoration of p53-dependent p21(WAF1/CIP1) expression after transfection of a genomic clone containing the p21(WAF1/CIP1) gene. Mol Cell Biol 20:1291-1298
185. Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE (2002) p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol 12:1817-1827
186. Nasmyth K (2002) Segregating sister genomes: the molecular biology of chromosome separation. Science 297:559-565
187. Niculescu AB 3rd, Chen X, Smeets M, Hengst L, Prives C, Reed SI (1998) Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18:629-643
188. Bates S, Ryan KM, Phillips AC, Vousden KH (1998) Cell cycle arrest and DNA endoreduplication following p21 Waf1/Cip1 expression. Oncogene 17:1691-1703
189. Stewart ZA, Leach SD, Pietenpol JA (1999) p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol Cell Biol 19:205-215
190. Andreassen PR, Margolis RL (1994) Microtubule dependency of p34cdc2 inactivation and mitotic exit in mammalian cells. J Cell Biol 127:789-802
191. Khan SH, Wahl GM (1998) p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res 58:396-401
192. Kung AL, Sherwood SW, Schimke RT (1990) Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci U S A 87:9553-9557
193. Lanni JS, Jacks T (1998) Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18:1055-1064
194. Minn AJ, Boise LH, Thompson CB (1996) Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev 10:2621-2631
195. Pourquier P, Pommier Y (2001) Topoisomerase I-mediated DNA damage. Adv Cancer Res 80:189-216
196. Zhu J, Schiestl RH (1996) Topoisomerase I involvement in illegitimate recombination in Saccharomyces cerevisiae. Mol Cell Biol 16:1805-1812
197. Labib K, Diffley JF (2001) Is the MCM2-7 complex the eukaryotic DNA replication fork helicase? Curr Opin Genet Dev 11:64-70
198. Chiang YC, Teng SC, Su YN, Hsieh FJ, Wu KJ (2003) c-MYC directly regulates the transcription of NBS1 gene involved in DNA double-strand break repair. J Biol Chem 13:13
199. Schorl C, Sedivy JM (2003) Loss of protooncogene c-Myc function impedes G(1) phase progression both before and after the restriction point. Mol Biol Cell 14:823-835
200. Williams BR, Mirzoeva OK, Morgan WF, Lin J, Dunnick W, Petrini JH (2002) A murine model of Nijmegen breakage syndrome. Curr Biol 12:648-653
201. Grandori C, Wu KJ, Fernandez P, Ngouenet C, Grim J, Clurman BE, Moser MJ, Oshima J, Russell DW, Swisshelm K, Frank S, Amati B, Dalla-Favera R, Monnat RJ Jr (2003) Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev 17:1569-1574
202. Schar P (2001) DNA damage genome instability Spontaneous, and cancer-when DNA replication escapes control. Cell 104:329-332
203. Loeb LA (2001) A mutator phenotype in cancer. Cancer Res 61:3230-3239
204. Felsher DW, Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4:199-207
205. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G (1999) Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3:565-577
206. Pelengaris S, Khan M, Evan GI (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109:321-334
207. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, Cardiff RD, Chodosh LA (2001) c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7:235-239
208. Ilyas M, Straub J, Tomlinson IP, Bodmer WF (1999) Genetic pathways in colorectal and other cancers. Eur J Cancer 35:1986-2002
209. Ugolini F, Charafe-Jauffret E, Bardou VJ, Geneix J, Adelaide J, Labat-Moleur F, Penault-Llorca F, Longy M, Jacquemier J, Birnbaum D, Pebusque MJ (2001) WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 20:5810-5817
210. Smalley MJ, Dale TC (1999) Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev 18:215-230
211. You Z, Saims D, Chen S, Zhang Z, Guttridge DC, Guan KL, MacDougald OA, Brown AM, Evan G, Kitajewski J, Wang CY (2002) Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol 157:429-440
212. Smalley MJ, Dale TC (2001) Wnt signaling and mammary tumorigenesis. J Mammary Gland Biol Neoplasia 6:37-52
213. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, Cardiff RD, Chodosh LA (2003) Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 17:488-501
214. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297:102-104
215. Arnold I, Watt FM (2001) c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol 11:558-568